CN110996687A - 用于治疗再狭窄的联合疗法 - Google Patents

用于治疗再狭窄的联合疗法 Download PDF

Info

Publication number
CN110996687A
CN110996687A CN201880049930.2A CN201880049930A CN110996687A CN 110996687 A CN110996687 A CN 110996687A CN 201880049930 A CN201880049930 A CN 201880049930A CN 110996687 A CN110996687 A CN 110996687A
Authority
CN
China
Prior art keywords
composition
temsirolimus
blood vessel
lesion
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880049930.2A
Other languages
English (en)
Chinese (zh)
Inventor
K·P·塞瓦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mercator MedSystems Inc
Original Assignee
Mercator MedSystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mercator MedSystems Inc filed Critical Mercator MedSystems Inc
Publication of CN110996687A publication Critical patent/CN110996687A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880049930.2A 2017-05-26 2018-05-25 用于治疗再狭窄的联合疗法 Pending CN110996687A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511797P 2017-05-26 2017-05-26
US62/511,797 2017-05-26
US201862624528P 2018-01-31 2018-01-31
US62/624,528 2018-01-31
PCT/US2018/034713 WO2018218182A1 (en) 2017-05-26 2018-05-25 Combination therapy for treatment of restenosis

Publications (1)

Publication Number Publication Date
CN110996687A true CN110996687A (zh) 2020-04-10

Family

ID=64397143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049930.2A Pending CN110996687A (zh) 2017-05-26 2018-05-25 用于治疗再狭窄的联合疗法

Country Status (8)

Country Link
US (4) US10576063B2 (enExample)
EP (1) EP3629774A4 (enExample)
JP (1) JP7137584B2 (enExample)
KR (1) KR20200008166A (enExample)
CN (1) CN110996687A (enExample)
AU (1) AU2018272061A1 (enExample)
CA (1) CA3064780A1 (enExample)
WO (1) WO2018218182A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11369574B2 (en) * 2017-05-17 2022-06-28 Massachusetts Institute Of Technology Self-righting systems and related components and methods
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
CN110996687A (zh) * 2017-05-26 2020-04-10 墨卡托医疗系统公司 用于治疗再狭窄的联合疗法
WO2019178228A1 (en) 2018-03-14 2019-09-19 Mercator Medsystems, Inc. Medical instrument and medical method for localized drug delivery
AU2019269636A1 (en) 2018-05-17 2020-11-19 Massachusetts Institute Of Technology Systems for electrical stimulation
US11497552B2 (en) 2019-07-09 2022-11-15 Juad, Inc. Apparatus, systems and methods for transvascular access to the brain
CA3165259A1 (en) * 2019-12-19 2021-06-24 Triviumvet Dac Veterinary formulations comprising rapamycin and methods of using the same for treating animal diseases
CA3210722A1 (en) 2021-03-11 2022-09-15 Alpha Tau Medical Ltd. Radiotherapy applicator
EP4363050A4 (en) 2021-06-30 2025-05-07 Alpha Tau Medical Ltd. Radiotherapy applicator with perpendicular or angled radial dispensing

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189941A1 (en) * 2002-01-22 2006-08-24 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US20100082095A1 (en) * 2008-09-29 2010-04-01 Abbott Cardiovascular Systems Inc. Coatings Including Dexamethasone Derivatives And Analogs And Olimus Drugs
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
KR20170051261A (ko) * 2015-11-02 2017-05-11 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1044174A (en) 1912-03-18 1912-11-12 Orville Bray Elevator automatic safety appliance.
HU212760B (en) 1989-06-20 1997-02-28 Denes Method and device for the apportion of chemical materials into the vein wall
US5527532A (en) 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5196024A (en) 1990-07-03 1993-03-23 Cedars-Sinai Medical Center Balloon catheter with cutting edge
US5270047A (en) 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
US5538504A (en) 1992-07-14 1996-07-23 Scimed Life Systems, Inc. Intra-extravascular drug delivery catheter and method
DE4235506A1 (de) 1992-10-21 1994-04-28 Bavaria Med Tech Katheter zur Injektion von Arzneimitteln
EP0689465A1 (en) 1993-03-18 1996-01-03 Cedars-Sinai Medical Center Drug incorporating and releasing polymeric coating for bioprosthesis
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6009877A (en) 1994-06-24 2000-01-04 Edwards; Stuart D. Method for treating a sphincter
US5645564A (en) 1995-05-22 1997-07-08 Regents Of The University Of California Microfabricated therapeutic actuator mechanisms
US5722989A (en) 1995-05-22 1998-03-03 The Regents Of The University Of California Microminiaturized minimally invasive intravascular micro-mechanical systems powered and controlled via fiber-optic cable
US5746716A (en) 1995-07-10 1998-05-05 Interventional Technologies Inc. Catheter for injecting fluid medication into an arterial wall
US5693029A (en) 1995-07-10 1997-12-02 World Medical Manufacturing Corporation Pro-cell intra-cavity therapeutic agent delivery device
US20020001581A1 (en) 1996-03-04 2002-01-03 Lynch Carmel M. Methods for transducing cells in blood vessels using recombinant AAV vectors
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5911737A (en) 1997-02-28 1999-06-15 The Regents Of The University Of California Microfabricated therapeutic actuators
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
US20040067197A1 (en) 1997-11-26 2004-04-08 Guy Leclerc Radiolabeled DNA carrier, method of preparation and therapeutic uses thereof
US6059766A (en) 1998-02-27 2000-05-09 Micro Therapeutics, Inc. Gynecologic embolotherapy methods
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6210392B1 (en) 1999-01-15 2001-04-03 Interventional Technologies, Inc. Method for treating a wall of a blood vessel
US7094765B1 (en) 1999-01-29 2006-08-22 Avi Biopharma, Inc. Antisense restenosis composition and method
US6302870B1 (en) 1999-04-29 2001-10-16 Precision Vascular Systems, Inc. Apparatus for injecting fluids into the walls of blood vessels, body cavities, and the like
US6283947B1 (en) 1999-07-13 2001-09-04 Advanced Cardiovascular Systems, Inc. Local drug delivery injection catheter
US6494862B1 (en) 1999-07-13 2002-12-17 Advanced Cardiovascular Systems, Inc. Substance delivery apparatus and a method of delivering a therapeutic substance to an anatomical passageway
PT1214077E (pt) 1999-09-21 2004-05-31 Inst Cardiologie Montreal Libertacao local de estradiol 17-beta para melhorar a funcao vascular do endotelio na sequencia de feridas vasculares
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20160287708A9 (en) 2000-03-15 2016-10-06 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6602241B2 (en) 2001-01-17 2003-08-05 Transvascular, Inc. Methods and apparatus for acute or chronic delivery of substances or apparatus to extravascular treatment sites
US6625486B2 (en) 2001-04-11 2003-09-23 Advanced Cardiovascular Systems, Inc. Method and apparatus for intracellular delivery of an agent
US20020188310A1 (en) 2001-06-08 2002-12-12 Seward Kirk Partick Microfabricated surgical device
US6547303B1 (en) 2001-08-13 2003-04-15 Johnson Controls Technology Company Pivoting seating system
US6860867B2 (en) 2001-09-20 2005-03-01 The Regents Of The University Of California Method of interventional surgery
US6547803B2 (en) 2001-09-20 2003-04-15 The Regents Of The University Of California Microfabricated surgical device for interventional procedures
CA2466432A1 (en) 2001-11-08 2003-05-15 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
US7247149B2 (en) 2001-12-20 2007-07-24 Advanced Cardiovascular Systems, Inc. Contact and penetration depth sensor for a needle assembly
BR0306858A (pt) 2002-01-10 2004-11-03 Novartis Ag Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
AU2003205315A1 (en) 2002-01-22 2003-09-02 Endobionics, Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US10441747B2 (en) 2002-01-22 2019-10-15 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US7744584B2 (en) 2002-01-22 2010-06-29 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US20070078620A1 (en) 2002-02-13 2007-04-05 Mercator Medsystems Inc. Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia
US8574195B2 (en) 2002-06-10 2013-11-05 Advanced Cardiovascular Systems, Inc. Systems and methods for detecting tissue contact and needle penetration depth using static fluid pressure measurements
US7500986B2 (en) 2002-07-11 2009-03-10 Medtronic Vascular, Inc. Expandable body having deployable microstructures and related methods
WO2004011000A1 (en) 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
US7008411B1 (en) 2002-09-30 2006-03-07 Advanced Cardiovascular Systems, Inc. Method and apparatus for treating vulnerable plaque
US20040162542A1 (en) 2002-12-03 2004-08-19 Endobionics, Inc. Methods and systems for treating the vasculature with estrogens
WO2004082491A1 (en) 2003-03-18 2004-09-30 Robert Ganz Method and device for delivering a substance to tissue layers
US20050163711A1 (en) 2003-06-13 2005-07-28 Becton, Dickinson And Company, Inc. Intra-dermal delivery of biologically active agents
US20050182071A1 (en) 2003-09-16 2005-08-18 Endobionics, Inc. Methods and systems for inhibiting arrhythmia
US20050232965A1 (en) 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
EP1758633B1 (en) 2004-05-13 2015-03-18 Medtronic Vascular, Inc. Methods for compounding a therapeutic agent to the adventitia of a vessel
JP2005349202A (ja) 2004-06-08 2005-12-22 Cordis Corp 治療薬を組織内へ導入する器具および方法
CN100435755C (zh) 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 药物洗脱支架
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
EP2012794B1 (en) 2006-04-13 2014-09-17 The Trustees of Columbia University in the City of New York Compositions and intraluminal devices for inhibiting vascular stenosis
US20070269385A1 (en) 2006-05-18 2007-11-22 Mercator Medsystems, Inc Devices, methods, and systems for delivering therapeutic agents for the treatment of sinusitis, rhinitis, and other disorders
US7691080B2 (en) 2006-09-21 2010-04-06 Mercator Medsystems, Inc. Dual modulus balloon for interventional procedures
US20100092534A1 (en) 2008-10-10 2010-04-15 Medtronic Vascular, Inc. Combination Local Delivery Using a Stent
US20100233266A1 (en) 2009-03-13 2010-09-16 Cleek Robert L Articles and methods of treating vascular conditions
WO2010117077A1 (ja) 2009-04-10 2010-10-14 参天製薬株式会社 シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤
JP2010269857A (ja) 2009-05-19 2010-12-02 Canon Inc シート給送装置及び該装置を備えた画像形成装置
US8911766B2 (en) 2009-06-26 2014-12-16 Abbott Cardiovascular Systems Inc. Drug delivery compositions including nanoshells for triggered drug release
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス， エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9220716B2 (en) * 2011-07-26 2015-12-29 Children's Medical Center Corporation Methods and compositions for the treatment of proliferative vascular disorders
US20130035665A1 (en) 2011-08-05 2013-02-07 W. L. Gore & Associates, Inc. Polymer-Based Occlusion Devices, Systems and Methods
US9220759B2 (en) 2012-02-23 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
CN103284948A (zh) 2012-02-29 2013-09-11 单颖 负载西罗莫司类化合物或其衍生物的聚合物组合物的制备及应用
US20130303496A1 (en) 2012-05-08 2013-11-14 Abbott Cardiovascular Systems Inc. Method Of Treating Vascular Lesions
WO2014118696A2 (en) 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
WO2015081821A1 (zh) 2013-12-02 2015-06-11 北京键凯科技有限公司 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物
EP3250277B1 (en) 2015-01-26 2022-09-21 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
WO2017078405A1 (ko) 2015-11-02 2017-05-11 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 폐암 치료용 약학 조성물
KR102123715B1 (ko) 2016-08-16 2020-06-16 주식회사 엘지화학 고체 산화물 연료전지
EP4295906A3 (en) 2016-09-22 2024-02-21 Mercator Medsystems, Inc. Treatment of restenosis using temsirolimus
CN110996687A (zh) 2017-05-26 2020-04-10 墨卡托医疗系统公司 用于治疗再狭窄的联合疗法
CN116710103A (zh) 2020-10-01 2023-09-05 墨卡托医疗系统公司 用于静脉血栓形成的血管周围抗炎疗法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
US20060189941A1 (en) * 2002-01-22 2006-08-24 Mercator Medsystems, Inc. Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation
US20100082095A1 (en) * 2008-09-29 2010-04-01 Abbott Cardiovascular Systems Inc. Coatings Including Dexamethasone Derivatives And Analogs And Olimus Drugs
KR20170051261A (ko) * 2015-11-02 2017-05-11 아주대학교산학협력단 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER D. OWENS ET AL.: "Safety and Feasibility of Adjunctive Dexamethasone Infusion into the Adventitia of the Femoro-popliteal Artery Following Endovascular Revascularization", 《J VASC SURG.》 *

Also Published As

Publication number Publication date
WO2018218182A1 (en) 2018-11-29
US10576063B2 (en) 2020-03-03
AU2018272061A1 (en) 2020-01-02
JP7137584B2 (ja) 2022-09-14
EP3629774A1 (en) 2020-04-08
US20180353488A1 (en) 2018-12-13
US20240024296A1 (en) 2024-01-25
US10925863B2 (en) 2021-02-23
CA3064780A1 (en) 2018-11-29
JP2020521755A (ja) 2020-07-27
US20200101049A1 (en) 2020-04-02
US20210236472A1 (en) 2021-08-05
EP3629774A4 (en) 2021-03-03
US11813249B2 (en) 2023-11-14
KR20200008166A (ko) 2020-01-23

Similar Documents

Publication Publication Date Title
US20240024296A1 (en) Combination therapy for treatment of restenosis
US20250120954A1 (en) Treatment of restenosis using temsirolimus
US11207449B2 (en) Methods and materials for treating blood vessels
WO2009068573A1 (en) A catheter based medical device and method for delivery of a therapeutic agent
US20250073014A1 (en) Methods, devices and systems for treating neointimal growth
HK1227672A1 (en) Maintenance of bronchial patency by local delivery of cytotoxic, cytostatic, or anti-neoplastic agent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20200410

Assignee: Shenzhen Xinlitai Medical Equipment Co.,Ltd.

Assignor: MERCATOR MEDSYSTEMS, Inc.

Contract record no.: X2022990001002

Denomination of invention: Combined therapy for restenosis

License type: Exclusive License

Record date: 20221230

EE01 Entry into force of recordation of patent licensing contract
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410

WD01 Invention patent application deemed withdrawn after publication